Braveheart Bio IPO Indicating $25.50/Share On 310K Shares; IPO Priced At $18/Share

Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?

Braveheart Bio Chairman Chris Viehbacher purchased 83,333 shares worth $1.5 million at the company's IPO price of $18 per share on August 7, 2026, expanding his direct stake by 16%. The insider purchase, combined with strong IPO demand and positive Phase 2 trial results for the company's lead cardiac myosin inhibitor candidate, signals bullishness around the clinical-stage biotech company.

8-K filing — Braveheart Bio, Inc. (BRVE)

Filed: 2026-08-07 AccNo: 0001628280-26-054842 Size: 221 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

Braveheart Bio IPO Opens At $30.20/Shares; IPO Priced At $18/Share

Braveheart Bio IPO Indicating $31/Share; IPO Priced At $18/Share